Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that when ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.

The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

Theratechnologies (THTX) stock gains as a new formulation of its best selling drug Egrifta is cleared by the FDA. Read more ...

The new formula will replace EGRIFTA SV and treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.

Beauty and personal care manufacturer kdc/one and India’s Clarion Group have announced a joint venture to strengthen beauty ...

First-in-human study evaluating a novel long-acting injectable antiretroviral therapy provides promising early results on its ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.

Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...